Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma

Hepatology

Volumn 45, Issue 4, 2007, Pages 938-947

  Wurmbach, Elisa ^a   Chen, Ying Bei ^a   Khitrov, Greg ^a   Zhang, Weijia ^a   Roayaie, Sasan ^a   Schwartz, Myron ^a   Fiel, Isabel ^a   Thung, Swan ^a   Mazzaferro, Vincenzo ^b   Bruix, Jordi ^c   Bottinger, Erwin ^a   Friedman, Scott ^a   Waxman, Samuel ^a   Llovet, Josep M ^a,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA PRIMASE; ERYTHROPOIETIN; HYALURONOAN MEDIATED MOTILITY RECEPTOR; JANUS KINASE; MICROCEPHALY ASSOCIATED PROTEIN; NEU DIFFERENTIATION FACTOR; RECEPTOR PROTEIN; STAT PROTEIN; TOLL LIKE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER INCIDENCE; CANCER STAGING; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA REPAIR; DNA REPLICATION; DYSPLASIA; GENE EXPRESSION; GENETIC ANALYSIS; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOLECULAR MODEL; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; GENOME, HUMAN; HEPATITIS C; HUMANS; LIVER NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247549347     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21622     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
3. Llovet JM, Burroughs A. Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-1917.
4. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-219.
5. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346.
6. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-687.
7. Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol 2006;44:798-805.
8. Delpuech O, Trabut JB, Carnot F, Feuillard J, Brechot C, Kremsdorf D. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene 2002;21:2926-2937.
9. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129-2137.
10. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 2002;62:3939-3944.
11. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9: 416-423.
12. Smith MW, Yue ZN, Geiss GK, Sadovnikova NY, Carter VS, Boix L, et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003;63:859-864.
13. Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. HEPATOLOGY 2005;42:809-818.
14. Kurokawa Y, Matoba R, Takemasa I, Nagano H, Dono K, Nakamori S, et al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 2004;41:284-291.
15. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-929.
16. Lee JS, Chu IS, Heo J, Calvist DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. HEPATOLOGY 2004;40:667-676.
17. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416.
18. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004;127:S113-S119.
19. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M. et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. HEPATOLOGY 2003;37:198-207.
20. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
21. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, et al. A molecular signature to discriminate dysplastic nodules from earlv hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131:1758-1767.
22. International Working Party. Terminology of nodular hepatocellular lesions. International Working Party. HEPATOLOGY 1995;22:983-993.
23. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MI-AME)-toward standards for microarray data. Nat Genet 2001;29:365-371.
24. Wurmbach E, Yuen T, Sealfon SC. Focused microarray analysis. Methods 2003;31:306-316.
25. Albanis E, Friedman SL. Antifibrotic agents for liver disease. Am J Transplant 2006;6:12-19.
26. Bieche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005;332:130-144.
27. Patil MA, Chua MS, Pan KH, Lin R, Lih CJ, Cheung ST, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005;24:3737-3747.
28. Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, Wang SM, et al. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005;86:127-141.
29. Yang CW, Su JY, Tsou AP, Chau GY, Liu HL, Chen CH, et al. Integrative genomics based identification of potential human hepatocarcinogenesis-associated cell cycle regulators: RHAMM as an example. Biochem Biophys Res Commun 2005;330:489-497.
30. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005;42:1208-1236.
31. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
32. Patadis V, Bieche I, Dargere D, Laurendeau I, Laurent C, Bioulac Sage P, et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003;163:733-741.
33. Yotov WV, Hamel H, Rivard GE, Champagne MA, Russo PA, Leclerc JM, et al. Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma. Genes Chromosomes Cancer 1999;26:62-69.
34. Kouprina N, Pavlicek A, Collins NK, Nakano M, Noskov VN, Ohzeki J, et al. The microcephaly ASPM gene is expressed in proliferating tissues and encodes for a mitotic spindle protein. Hum Mol Genet 2005;14:2155-2165.
35. Hall CL, Yang B, Yang X, Zhang S, Turley M, Samuel S, et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 1995;82:19-26.
36. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new thetapeutic targets. Semin Liver Dis 2005;25:212-225.
37. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120: 1763-1773.
38. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, et al. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol 2005;43:854-862.
39. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-1128.
40. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004;64:6854-6857.
41. Lin W, Choe WH, Hiasa Y, Kamegaya Y, Blackard JT, Schmidt EV, et al. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1 Gastroenterology 2005;128:1034-1041.
42. Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 2006;66: 2048-2058.
43. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RT, et al. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptot function and triggering apoptosis via caspase-3 activation. J Biol Chem 2006;281:26408-26418.
44. Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer CG, et al. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest 2003;83:429-434.
45. Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006;27:748-757.
46. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003;113:881-889.
47. Farazi PA, Glickman J, Jiang S, Yu A, Rudolph KL, DePinho RA. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 2003;63:5021-5027.
48. Kienitz A, Vogel C, Morales I, Muller R, Bastians H. Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene 2005; 24:4301-4310.
49. Gramantieri L, Chieco P, Giovannini C, Lacchini M, Trere D, Grazi GL, et al. GADD45-alpha expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation. Hum Pathol 2005; 36:1154-1162.
50. Zhao M, Kim YT, Yoon BS, Kim SW, Kang MH, Kim SH, et al. Expression profiling of cyclin B1 and D1 in cervical carcinoma. Exp Oncol 2006;28:44-48.